Chicago, IL (PRWEB) August 20, 2013
The birth control safety center at DrugRisk.com is announcing updated information on the site for women who have used the contraceptives Yaz or Yasmin. The maker of the drugs recently reported they have spent nearly $1.5 billion so far to settle claims alleging blood clot injuries*.
DrugRisk.com provides the latest news, research, safety alerts, recalls and litigation updates to patients taking popular prescription drugs. Visitors can find out if others are experiencing similar side effects and decide if they need legal advice.
The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots.
Due to the number of patients who filed a Yaz lawsuit alleging side effects, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)). The latest court records still show 9,998 cases pending****.
Now, DrugRisk has added information showing the maker of Yaz and Yasmin, Bayer, has spent over $1.4 billion already to settle approximately 6,760 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*. This amounts to over $200,000 per case.
Anyone who suffered blood clots, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisk Center or speak with a lawyer about their legal options.
Due to the specialized nature of federal MDL courts, patients should seek a lawyer with experience in defective drug litigation. DrugRisk only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Bayer Stockholder’s newsletter Pg. 64, 7/31/13; stockholders-newsletter-q2-2013.bayer.com/en/bayer-stockholders-newsletter-2q-2013.pdfx
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****JPML, 7/10/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-July-10-2013.pdf